Skip to main content
Premium Trial:

Request an Annual Quote

France s ExonHit Raises 30M Euros in Private Financing Round

NEW YORK, Dec. 3 – French genomics company ExonHit Therapeutics said Monday it raised 30 million euros ($26.8 million) in a third round of private financing.

The Paris-based company, which develops therapeutics and diagnostics based on the analysis of alternative splicing events, said that Dresdner Kleinwort Capital of the UK, Danske Bank of Denmark, and France’s LCF E. de Rothschild and Sudinnova participated in the financing round. 

Previous investors BNP-Paribas' Banexi Venture III, CDC Innovation, AGF Private Equity, Oxford Bioscience Partners, and Sofinnova Partners also contributed. 

ExonHit Therapeutics' previously raised 14 million in a second round of financing that closed a little more than one year ago. 

The company said it would use the latest cash infusion to further develop its therapeutics and diagnostics and to bring them through clinical development. 

The company is currently developing treatments for Amyotrophic Lateral Scleroris, or Lou Gehrig’s disease, and other central nervous system afflictions.

Founded in 1997, ExonHit Therapeutics has a US subsidiary in Gaithersburg, Md. The company expects to generate revenues from products and services and anticipates reaching profitability in 2004.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.